The Effect of Nandrolone Decanoate and Leucine on Muscle Loss

Overview

A decrease in muscle mass can have a profound impact on quality of life, as it can lead to decreased strength, insulin resistance, lower basal metabolic rate and obesity. With this study we investigate whether ingesting leucine or getting a ND injection will reduce the loss of muscle mass and strength.

Full Title of Study: “The Effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2016

Interventions

  • Behavioral: Inactivity
    • Inactivity
  • Drug: ND
    • 1 nandrolone decanoate injection
  • Dietary Supplement: Leu
    • Leucine supplements

Arms, Groups and Cohorts

  • Experimental: Leu during inactivity
    • Leucine supplements
  • Experimental: ND during inactivity
    • Nandrolone injection

Clinical Trial Outcome Measures

Primary Measures

  • CSA Quadriceps (CT scan)
    • Time Frame: 7 days
    • CT scan

Secondary Measures

  • Muscle strength as measured by 1RM test
    • Time Frame: 7 days
  • Muscle fiber type and CSA as measured by histochemistry from the muscle biopsy
    • Time Frame: 7 days

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy men 18-35 years – BMI between 18.5 and 30 kg/m2 Exclusion Criteria:

  • (Family) history of thromboembolic events – Smoking – Recent surgery (within 6 months prior to the study) – Performing progressive resistance training more than three times per week in the past year – Any back/leg/knee/shoulder complaints which may interfere with the use of crutches – Current systemic use of corticosteroids, anabolic steroids, growth hormone, testosterone, nandrolone, protein supplements, immunosuppressants or insulin, blood sugar decreasing medication or EPO – All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis) – Use of anti-coagulants – Pre-existing renal disease or those with a potential risk for renal dysfunction (diabetes, hypertension, reduced glomerular filtration rate) – Liver disease – Heart failure – Migraine – Allergy to nuts or soy – High blood pressure (>140 mmHg systolic and >90 mmHg diastolic) In case of doubt, in- or exclusion of subject will be discussed with responsible physician or principal investigator.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Maastricht University Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Luc van Loon, Prof. Dr., Principal Investigator, Maastricht University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.